Skip to Content

College of Pharmacy

Faculty and Staff

Chengwen Teng, Pharm.D., Ph.D.

Title: Assistant Professor
Department: Clinical Pharmacy and Outcomes Sciences (CPOS)
College of Pharmacy
Email: tengc@mailbox.sc.edu
Phone: 803-608-5549
Office: College of Pharmacy
715 Sumter Street - CLS 311M
Columbia, SC 29208
LinkedIn: My LinkedIn profile
Chengwen Teng portrait

Education

Ph.D.  Translational Science, University of Texas at Austin, 2019
Pharm.D.  University of Oklahoma Health Sciences Center, 2017
M.S.  Biological Sciences, University of Southern Mississippi, 2012
B.S.  Biology, Wuhan University, China, 2010

Background

Chengwen Teng, Pharm.D., Ph.D., M.S., is an Assistant Professor at the University of South Carolina College of Pharmacy. He earned his Ph.D. in Translational Science from the University of Texas at Austin, his Pharm.D. from the University of Oklahoma Health Sciences Center, a Master of Science degree in biological sciences from the University of Southern Mississippi, and a Bachelor of Science degree in biology from Wuhan University. Dr. Teng is a pharmacist licensed in the United States. 

Dr. Teng is passionate about improving human health and promoting the safe use of medications. Currently, he is working on the identification of new adverse drug reactions, drug-drug interactions, and drug-disease interactions, and is comparing drug safety and effectiveness profiles using spontaneous reporting systems, electronic health records, and other databases. In addition to health outcomes research, Dr. Teng had research experience in pharmacology, immunology, and biochemistry. 

Dr. Teng is a member of the Professional Society for Health Economics and Outcomes Research (ISPOR), American Association of Colleges of Pharmacy, American Pharmacists Association, American Society of Health System Pharmacists, and Society of Infectious Diseases Pharmacists. 

Research Interests

  • Pharmacovigilance
  • Pharmacoepidemiology
  • Big Data
  • Pharmacology

Publications

Teng C, Frei CR. Delirium associations with antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS). Drugs Real World Outcomes. 2022;9(1):23-9.

Yunusa I, Teng C, Karaye IM, Crounse E, Alsahali S, Maleki N. Comparative safety signal assessment of hospitalization associated with the use of atypical antipsychotics. Front Psychiatry. 2022;13:917351.

Eaves AC, Teng C, Evoy KE, Frei CR. Retrospective cohort evaluating the comparative effectiveness of ceftaroline and daptomycin as first-line therapies for inpatient treatment of diabetic foot infection in the United States Veterans Health Care System. Drugs Real World Outcomes. 2022.

Boyd NK, Teng C, Frei CR. Brief overview of approaches and challenges in new antibiotic development: a focus on drug repurposing. Front Cell Infect Microbiol 2021;11:684515. DOI: 10.3389/fcimb.2021.684515.

Frei CR, Le H, McHugh D, Ryan K, Jones X, Galley S, Franklin K, Baus CJ, Tavera J, Janania-Martinez M, Gregorio D, Ananth S, Uribe R, Surapaneni P, Espinoza-Gutarra M, Song MM, Teng C, Obodozie-Ofoegbu OO, Nooruddin Z. Outcomes in chronic lymphocytic leukemia patients on novel agents in the US Veterans Health Administration System. Leuk Lymphoma 2021;62(7):1664-1673. DOI: 10.1080/10428194.2021.1876863.

Boyd NK, Lee GC, Teng C, Frei CR. In vitro activity of non-antibiotic drugs against Staphylococcus aureus clinical strains. J Glob Antimicrob Resist 2021;27:167-171. DOI: 10.1016/j.jgar.2021.09.003.

Kennedy KE, Teng C, Patek TM, Frei CR. Hypoglycemia associated with antibiotics alone and in combination with sulfonylureas and meglitinides: an epidemiologic surveillance study of the FDA Adverse Event Reporting System (FAERS). Drug Saf. 2020;43(4):363-9.

Patek TM, Teng C, Kennedy KE, Alvarez CA, Frei CR. Comparing acute kidney injury reports among antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS). Drug Saf. 2020;43(1):17-22.

Teng C, Baus C, Wilson JP, Frei CR. Rhabdomyolysis associations with antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS). Int J Med Sci. 2019;16(11):1504-9.

Mootz ML, Britt RS, Mootz AA, Lee GC, Reveles KR, Evoy KE, Teng C, Frei CR. Comparative-effectiveness of ceftaroline and daptomycin as first-line MRSA therapy for patients with sepsis admitted to hospitals in the United States Veterans Health Care System. Hosp Pract (1995). 2019;47(4):186-91.

Obodozie-Ofoegbu OO, Teng C, Mortensen EM, Frei CR. Antipseudomonal monotherapy or combination therapy for older adults with community-onset pneumonia and multidrug-resistant risk factors: a retrospective cohort study. Am J Infect Control. 2019;47(9):1053-8.

Teng C, Walter EA, Gaspar DKS, Obodozie-Ofoegbu OO, Frei CR. Torsades de pointes and QT prolongation associations with antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System. Int J Med Sci. 2019;16(7):1018-22.

Teng C, Reveles KR, Obodozie-Ofoegbu OO, Frei CR. Clostridium difficile infection risk with important antibiotic classes: an analysis of the FDA Adverse Event Reporting System. Int J Med Sci. 2019;16(5):630-5.

Evoy KE, Teng C, Encarnacion VG, Frescas B, Hakim J, Saklad S, et al. Comparison of quetiapine abuse and misuse reports to the FDA Adverse Event Reporting System with other second-generation antipsychotics. Subst Abuse. 2019;13:1178221819844205.

Rao G, Nkepang G, Xu J, Yari H, Houson H, Teng C, et al. Ubiquitin receptor RPN13 mediates the inhibitory interaction of diphenyldihaloketones CLEFMA and EF24 with the 26S proteasome. Front Chem. 2018;6:392.

Rao G, Houson H, Nkepang G, Yari H, Teng C, Awasthi V. Induction of gut proteasome activity in hemorrhagic shock and its recovery by treatment with diphenyldihaloketones CLEFMA and EF24. Am J Physiol Gastrointest Liver Physiol. 2018;315(2):G318-G27.

Rao G, Croft B, Teng C, Awasthi V. Ubiquitin-proteasome system in neurodegenerative disorders. J Drug Metab Toxicol. 2015;6(4).

Wang R, Teng C, Spangler J, Wang J, Huang F, Guo YL. Mouse embryonic stem cells have underdeveloped antiviral mechanisms that can be exploited for the development of mRNA-mediated gene expression strategy. Stem Cells Dev. 2014;23(6):594-604.

Treat NJ, Smith D, Teng C, Flores JD, Abel BA, York AW, et al. Guanidine-containing methacrylamide (co)polymers via aRAFT: toward a cell penetrating peptide mimic. ACS Macro Lett. 2012;1(1):100-4.

Mao AP, Li S, Zhong B, Li Y, Yan J, Li Q, Teng C, Shu HB. Virus-triggered ubiquitination of TRAF3/6 by cIAP1/2 is essential for induction of interferon-beta (IFN-beta) and cellular antiviral response. J Biol Chem. 2010;285(13):9470-6.

See more


 


Challenge the conventional. Create the exceptional. No Limits.

©